Form 4: Exelixis Executive Patrick J. Haley Reports Acquisition of Shares Through Restricted Stock Units

EVP, Commercial of Exelixis, Patrick J. Haley, reports the acquisition of 47,718 shares of common stock through the vesting of restricted stock units (RSUs).

Summary

• Patrick J. Haley, EVP, Commercial at Exelixis, Inc., filed a Form 4 on February 28, 2025, reporting changes in beneficial ownership.
• The report details the acquisition of 47,718 shares of Exelixis common stock through the vesting of restricted stock units (RSUs) on February 26, 2025.
• These RSUs were granted under the Exelixis, Inc. 2017 Equity Incentive Plan.
• The RSUs vest in four equal installments, starting on May 15, 2026.
• Following the reported transactions, Haley directly owns 351,028 shares of common stock, including shares issuable upon vesting of RSUs.
• Haley also indirectly owns 23,539 shares through a spouse and 10,648 shares through a 401(k) plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating standard executive compensation practices. There are no explicit positive or negative implications for the company's performance.

Positives

• The acquisition of shares by an executive can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedule of the RSUs incentivizes the executive to remain with the company and contribute to its long-term success.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the RSUs suggests a continued relationship between the executive and the company.

Industry Context

This filing is a routine disclosure related to executive compensation and equity ownership, common in publicly traded companies. It provides transparency to investors regarding the alignment of management's interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation is a standard practice in the biotechnology industry to attract and retain talent.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize RSUs and stock options as part of their executive compensation packages.
• The vesting schedules and terms of these equity grants are typically benchmarked against industry peers to ensure competitiveness.

Stakeholder Impact

• Shareholders are informed about changes in executive ownership, providing transparency.
• Employees may view this as a positive sign of executive commitment.
• The impact on customers, suppliers, and creditors is likely minimal.

Key Dates